source
- Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitorEli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
- Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trialOruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…